Lecanemab

仑卡奈单抗

Report date: 2026/05/06 20:02:28

Base Information

Drug NameLecanemab
Drug Alias Namelecanemab-irmbAnti-amyloid beta protofibril antibodyLeqembiLEQEMBI乐意保 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionBeta amyloid A4 protein inhibitors
TargetsBeta amyloid A4 protein
Therapy Area/IndicationsCognitive DysfunctionAlzheimer DiseaseDementia
Global Approved IndicationsCognitive DysfunctionAlzheimer DiseaseDementia
Approved Indications in ChinaCognitive DysfunctionAlzheimer DiseaseDementia
Original Approved Country/TerritoryUnited States
Original Approved Date2023/01/06
Country/TerritoryMainland China(BOAO LECHENG)CanadaUnited States +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBioarctic Neuroscience
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineBiogen IncEisai Gmbh +[5] 
Inactive CompaniesBiogen US CorpZhejiang Provincial People’S HospitalEisai China Inc
Active IndicationsCognitive DysfunctionAlzheimer DiseaseDementia
Inactive IndicationsN/A

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG